Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial We analyzed a cohort ...

For Richard “Rocky” Kimball, a diagnosis of myelodysplastic syndromes, or MDS, necessitated a number of lifestyle changes.

Image courtesy of the U.S. Centers for Disease Control. Over the past 50 years, survival rates for a group of blood cancers known as myelodysplastic syndrome (MDS) have not improved, despite the ...

A Servier Pharmaceuticals drug acquired as part of a $1.8 billion deal has won an additional FDA approval as a treatment for a rare type of blood cancer carrying a specific mutation. The regulatory ...

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...

The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed higher-risk myelodysplastic syndrome, a form of blood cancer known as MDS, ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...